Mylan’s $9.9 Billion Proposed Acquisition of Meda

On February 10, 2016, Mylan N.V. announced a recommended public offer to the shareholders of Meda Aktiebolag (publ.) to tender all their shares in Meda to Mylan. Cravath represented Mylan in connection with this proposed transaction. The total offer consideration consists of a combination of cash and Mylan ordinary shares with a value at announcement of SEK 165 per Meda share. The total value of the offer for all Meda shares, including Meda net debt, is approximately SEK 83.6 billion or USD 9.9 billion.

The Cravath team was led by partners Mark I. Greene and Aaron M. Gruber and included associate William F. Roegge on M&A matters; partner George E. Zobitz and associates Raffael M. Fiumara and David J. Benhamou on finance matters; partners Eric W. Hilfers and Jonathan J. Katz and associate Matthew J. Bobby on executive compensation and benefits matters; partners Christine A. Varney and Yonatan Even and associates Margaret Segall D’Amico and Allison C. Davido on antitrust matters; partner Matthew Morreale on environmental matters; partner Thomas E. Dunn, senior attorney Kimberley S. Drexler and associate Zachary R. Smith on corporate matters; partners Stephen L. Gordon and J. Leonard Teti II and associate Kiran Sheffrin on tax matters; and partner David J. Kappos and associates Christopher P. Davis and Jason M. Sandler on intellectual property matters. Christopher J. Washington also worked on M&A matters and Noah X. DeBlasi also worked on finance matters.